MetLife, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MET research report →
Range $103 – $112
Price Chart
About the company
MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.
- CEO
- Michel Abbas Khalaf
- IPO
- 2000
- Employees
- 46,000
- HQ
- New York City, NY, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive long-term uptrend, trading above its 200-day moving average and well above the 52-week low. It is still below the 52-week high, so the setup looks like a consolidation within a broader advance rather than a broken trend.
Wall Street remains constructive: the consensus is Buy, with 26 Buy, 7 Hold, and no Sell ratings. The average target sits at 108.78 versus a 110 median, and recent target work has trended higher, including a fresh $112 call and multiple raises around the $109-$111 range.
The earnings cadence has been favorable, with four straight EPS beats and five beats in the last eight quarters. Next-year EPS estimates point higher to 11.1849 from a 7.65 TTM base, so shareholders should watch whether underwriting and investment income keep supporting that step-up.
The only clear discretionary signal is a large sale by CEO Michel Khalaf, while the rest of the activity is automatic award or exempt-related flow from directors and officers. That mix leans cautious on insider sentiment, but it does not show broad-based selling across the leadership group.
Profitability is solid for a life insurer, with a 19.92% ROE, 8.51% operating margin, and 6.21% net margin. Growth is also strong, with revenue up 18.2% year over year and earnings up 200.8%, while free cash flow reached $18.105 billion in the latest fiscal year.
MetLife screens as a steady large-cap life insurer with a beta of 0.773, so it tends to move less than the market. The valuation is modest at 10.07 times earnings, which leaves it cheaper than many growthier financials while still backed by a strong balance sheet.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $60.12B
- P/E
- 12.91
- Fwd P/E
- 9.35
- PEG
- 0.29
- P/S
- 0.76
- P/B
- 2.85
- EV/EBITDA
- 8.30
- Div Yield
- 2.35%
- Gross Margin
- 29.23%
- Op Margin
- 8.44%
- Net Margin
- 6.23%
- ROE
- 19.46%
- ROIC
- 0.97%
Latest fiscal year · YoY change
- Revenue
- $77.08B+10.2%
- Gross Profit
- $28.02B+47.5%
- Op Income
- $4.66B
- Net Income
- $3.38B-23.7%
- EPS
- $4.80-19.7%
- OCF Growth
- +19.8%
- FCF Growth
- +19.8%
- 52W High
- $106.72
- 52W Low
- $67.33
- 50D MA
- $99.04
- 200D MA
- $87.35
- Beta
- 0.77
- RSI (14)
- 41
- Avg Volume
- 3.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MetLife said third-quarter results set a record, with adjusted EPS up 22% ex-notables, broad-based business growth, and capital returns continuing at a strong pace.· November 5, 2026
- Adjusted EPS excluding notable items rose 22% to $2.85, with adjusted earnings up 17% to $1.8 billion; adjusted ROE was 19.6%.
- Variable investment income was a major tailwind at $720 million pretax, helped by private equity and venture capital returns above 4%.
- The direct expense ratio was 11.9%, and management said it remains on track to beat the 12.1% full-year target.
- Group Benefits, RIS, Asia, Latin America and EMEA all contributed; management emphasized no single business drove the quarter.
- Capital deployment stayed active: MetLife repurchased $650 million of shares in Q3, another $265 million in October, and held $3.4 billion of holding company cash and liquid assets at quarter-end.
MetLife reported net income of $2.4 billion, or $3.67 per share, and adjusted earnings of $1.8 billion, or $2.78 per share. Excluding notable items, adjusted earnings were $1.8 billion, up 17% year over year, and adjusted EPS was $2.85, up 22%. Adjusted ROE, excluding notables, was 19.6%, and adjusted book value per share rose 5% year over year to $59.41. Variable investment income was $720 million pretax, and the direct expense ratio was 11.9%. On the business side, Group Benefits adjusted earnings were $523 million, RIS $478 million, Asia $550 million, Latin America $229 million, EMEA $114 million, and MIM $63 million. Guidance-wise, management said it expects full-year RIS adjusted earnings to finish slightly north of the midpoint of its $1.6 billion to $1.8 billion outlook range, full-year MIM adjusted earnings within its $240 million to $280 million target range, and full-year VII to exceed its approximately $1.6 billion guidance. They also said the company remains on track to beat the 12.1% full-year direct expense ratio target and stay within the 65% to 75% free cash flow conversion range.
Michel Khalaf framed the quarter as proof that New Frontier is working, pointing to broad-based growth, attractive returns and disciplined capital management. He stressed that VII helped results but did not define them, and highlighted the mix of capital-light and capital-driven earnings engines as the company’s compounding model. His tone was confident and upbeat, repeatedly calling the quarter a record and saying the breadth behind the results was the key strength.
John McCallion focused on execution quality: adjusted EPS up 22%, adjusted ROE at 19.6%, and the direct expense ratio at 11.9%, even after absorbing about 50 basis points from PineBridge. He said net income exceeded adjusted earnings by about $570 million mainly because of a noneconomic accounting gain from higher interest rates, and noted holding company cash and liquid assets of $3.4 billion, within the $3 billion to $4 billion target buffer. He also cited $1.6 billion of hyperscaler exposure, $2.5 billion of data center exposure, no delinquencies or impairments in either category, and said the company returned about $1 billion to shareholders in the quarter, including $650 million of buybacks.
Analysts pressed on Group Benefits’ non-medical health ratio, particularly disability and dental trends, and management said disability was broadly in line with expectations despite some higher incidence and severity, while dental benefited from pricing and network actions. Questions also focused on whether favorable working-age mortality in group life was running its course; management said normalization should be gradual over years, not quarters, and near-term seasonality could lift mortality in Q4 and Q1. On capital allocation, management said nothing has changed on risk transfer or Chariot Re, that Chariot continues to progress, and that MetLife has no burning platform to do deals but would act if attractive opportunities emerged. Analysts also asked about M&A, and Michel said priorities remain organic growth first, with asset management and group as the two areas of interest, but only if deals clear a high bar versus buybacks and other uses of capital.
The bull case from this call is that MetLife is showing broad, not narrow, growth: earnings improved across multiple regions and businesses, not just from a single investment-income swing. Management also pointed to strong capital generation, high returns on new business, and continued buybacks, while saying expense discipline and AI-driven productivity could keep supporting margins. They sounded confident that the New Frontier strategy is compounding as intended.
The main risks discussed were the reliance on elevated VII, especially private equity and venture capital returns, which management acknowledged amplified the quarter. Group Benefits’ disability and mortality trends could normalize over time, and management said near-term seasonal upticks are likely in Q4 and Q1. RIS pension risk transfer volume was described as timing-sensitive and lumpy, and Latin America was hit by a negative encaje return in Chile, showing that market conditions can still swing results.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.7%
- Shares Outstanding
- 628.44M
- Float Shares
- 525.71M
of shares held by institutions
1,521 13F filers
Buy/sell ratio 2.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MET, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Aug 6, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Ritchie TorresHouse · NY15 | Sell | Jul 11, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 13, 25 | Filing → |
| Sheldon WhitehouseSenate · RI | Sell | Nov 19, 24 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Jan 17, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 31, 23 | Filing → |
| Sheldon WhitehouseSenate · RI | Sell | Sep 20, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 72.56M | ▲ 7.81M |
| Blackrock, Inc. | 51.94M | ▲ 155.65K |
| Vanguard Capital Management LLC | 35.13M | ▼ 348.95K |
| Dodge & Cox | 33.64M | ▼ 14.79M |
| Vanguard Portfolio Management LLC | 29.26M | ▼ 766.71K |
| State Street Corp | 25.10M | ▼ 232.49K |
| Price T Rowe Associates Inc | 20.57M | ▼ 713.78K |
| Geode Capital Management, LLC | 12.35M | ▼ 955.33K |
| Morgan Stanley | 12.16M | ▼ 369.61K |
| Pzena Investment Management LLC | 10.57M | ▼ 559.28K |
| Invesco Ltd. | 7.74M | ▲ 809.24K |
| Dimensional Fund Advisors LP | 7.59M | ▲ 397.42K |
Held by 2,016 ETFs
Biggest fund positions in MET by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Khalaf Michel | other | 94,578 |
| Nov 10, 26 | Khalaf Michel | other | 90,726 |
| Nov 10, 26 | Khalaf Michel | other | 34,608 |
| Nov 10, 26 | Khalaf Michel | sell | 187,425 |
| Nov 10, 26 | Khalaf Michel | other | 28,817 |
| Nov 10, 26 | Khalaf Michel | other | 94,578 |
| Nov 10, 26 | Khalaf Michel | other | 28,817 |
| Nov 10, 26 | Khalaf Michel | other | 34,608 |
| Nov 10, 26 | Khalaf Michel | other | 90,726 |
| Oct 1, 26 | Johnson Jeh C. | other | 544 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MET coverage
Recent articles, reports, and earnings notes.

MetLife (MET): Earnings Growth Meets Valuation Discipline
MetLife is delivering record adjusted EPS, broad-based segment growth, and disciplined capital returns, but the stock is already near fair value. The report rates MET a Buy on improving earnings power and diversified insurance exposure.

MetLife, Inc. (MET) gains on deep earnings beat analysis
MetLife, Inc. (MET) gained after beating earnings and revenue estimates, but the real story is deeper than the headline. This analysis breaks down the quarter’s revenue momentum, net income strength, segment performance, capital strategy, and analyst sentiment behind the stock’s move.

MetLife, Inc. (MET) gains on earnings beats
MetLife, Inc. (MET) gains 3.3% after reporting earnings beats, lifting shares as investors react to stronger-than-expected results and improved sentiment.
Want a deeper read on MET?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
MetLife Says Growth Plan Is Ahead of Schedule as Retirement Demand Rises
marketbeat.com · Nov 19
4 Insurance Stocks Retirees Can Count On for Reliable Passive Income
247wallst.com · Nov 19
MetLife, Inc. (MET) Presents at J.P. Morgan European Financials Conference Transcript
seekingalpha.com · Nov 19
Can MetLife's $370M Real Estate Debt Fund Support Fee Growth?
zacks.com · Nov 19
4 Insurance Dividend Stocks to Buy in December for High Yields and Staying Power
247wallst.com · Nov 18
MetLife Investment Management Closes $370 Million Opportunistic Real Estate Debt Fund
businesswire.com · Nov 17
MetLife Declares Fourth Quarter 2026 Preferred Stock Dividends
businesswire.com · Nov 16
THE BUSINESS COUNCIL FOR INTERNATIONAL UNDERSTANDING CELEBRATES MICHEL A. KHALAF, SUNNY VARKEY AT THE 2026 DWIGHT D.
prnewswire.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice